Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, Inc. (NYSE: AVTR) announced the retirement of Board Chairman Rajiv Gupta effective at the end of his term, with no re-election for the upcoming May 12, 2022, annual stockholders meeting. Gupta has been instrumental in Avantor's growth since August 2010, emphasizing vision and value creation. The company plans to announce a new Board chair soon. Gupta expressed pride in Avantor's impact on stakeholders and confidence in its future success under a capable management team.
Avantor, a leading global provider of mission-critical products, reported robust financial results for Q4 2021 and the full year. Q4 net sales reached $1.91 billion, a 6.5% increase, with net income rising to $94 million. The company achieved over 11% organic growth in 2021 and expanded Adjusted EBITDA margin by nearly 190 basis points to 19.8% for the full year. Notably, adjusted EPS surged by approximately 58% to $1.41. The completion of the Masterflex acquisition solidified its fluid management solutions, showcasing commitment to long-term growth strategies.
Avantor has declared a quarterly cash dividend of $0.78 per share on its 6.250% Series A Mandatory Convertible Preferred Stock. This dividend will be paid on February 15, 2022 to shareholders of record as of February 1, 2022. The stock has a liquidation preference of $50. Avantor operates in the biopharma, healthcare, education, and advanced technology sectors, serving over 225,000 customer locations worldwide.
Avantor, Inc. (NYSE: AVTR) is set to release its financial results for Q4 and the full year of 2021 on February 3, 2022, after the market closes. Following this, a conference call will take place on February 4, 2022, at 7:30 a.m. ET to discuss the results. Interested participants can join the call by dialing specific numbers for domestic or international access. A live webcast will also be available on Avantor's investor website, with a replay open until March 3, 2022.
Argosy Healthcare Partners has appointed Greg Mayer to lead portfolio company operations, bringing a wealth of experience from his previous roles at Avantor and Bank of America. Argosy Healthcare Partners, a lower middle market private equity investor, aims to support founder-owned healthcare companies in scaling their businesses. With over $2.3 billion in assets under management, Argosy focuses on life sciences tools and pharmaceutical services, positioning itself to enhance growth opportunities in the healthcare sector.
Summary not available.
Avantor, Inc. (NYSE: AVTR) has opened a new single-use logistics hub in Westminster, Massachusetts, enhancing its global biopharma supply chain. This facility, located near the existing manufacturing site in Devens, will streamline raw material storage, quality control, and distribution, enabling better support for the increasing demand for single-use solutions. In 2021, Avantor invested significantly in its single-use capabilities, including acquisitions like RIM Bio and Masterflex. The Westminster site marks Avantor's sixth U.S. location dedicated to single-use solutions, reinforcing its commitment to the biopharmaceutical industry.
Avantor, Inc. (NYSE: AVTR), a major player in mission-critical products for life sciences, will attend the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. CEO Michael Stubblefield will share insights on the company's priorities starting at 9:45 a.m. PT. A live webcast will be available on the investors section of their website, with a replay accessible until February 10, 2022. Avantor serves a vast customer base, facilitating research and production activities globally, aimed at advancing critical industries.
Avantor, a prominent global provider of critical products and services, will participate in a virtual fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021. The session, featuring President and CEO Michael Stubblefield, is scheduled to begin at 8:50 a.m. Eastern Time. Investors can access the live webcast through Avantor's website, with a replay available until December 31, 2021. Avantor serves over 225,000 customers in more than 180 countries, playing a vital role in research and development across various industries.
Avantor (NYSE: AVTR) has successfully completed its acquisition of the Masterflex bioprocessing business from Antylia Scientific, enhancing its capabilities in aseptic fluid transfer for bioproduction. This strategic move aims to strengthen Avantor's offerings in the growing biopharma market, particularly in the manufacturing of therapies and vaccines, including COVID-19. The acquisition received all necessary regulatory approvals and is expected to provide comprehensive solutions to complex bioproduction challenges.